MedTrace Logo

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

NCT00403130 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2019-02-20

Study results available
· View outcomes & findings →

Summary

Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.

Conditions

Interventions

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles

DRUG

Bevacizumab

Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • George Albert Fisher

    lead OTHER

Principal Investigators

  • George A Fisher, MD, PhD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2010-09-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403130 on ClinicalTrials.gov